1.10

0.90% -0.01

Opko Health Inc (OPK)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt OPK? Forum Prognose

Schlusskurs vom Vortag:

$1.11

Offen:

$1.1

24-Stunden-Volumen:

1.34M

Relative Volume:

0.58

Marktkapitalisierung:

$838.15M

Einnahmen:

$581.12M

Nettoeinkommen (Verlust:

$-212.92M

KGV:

-4.0175

EPS:

-0.2738

Netto-Cashflow:

$-174.22M

1W Leistung:

-1.79%

1M Leistung:

-5.98%

6M Leistung:

-14.06%

1J Leistung:

-12.70%

1-Tages-Spanne:

$1.08

$1.11

1-Wochen-Bereich:

$1.08

$1.15

52-Wochen-Spanne:

$0.9769

$1.60

Opko Health Inc Stock (OPK) Company Profile

Firmenname

Opko Health Inc

Sektor

Healthcare (1107)

Branche

Diagnostics & Research (52)

Telefon

305-575-4181

Adresse

4400 BISCAYNE BLVD., MIAMI, FL

Mitarbeiter

2,275

Twitter

Nächster Verdiensttermin

2026-04-28

Neueste SEC-Einreichungen

OPK's Discussions on Twitter

Compare OPK vs TMO, DHR, IDXX, WAT, A

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OPK Opko Health Inc	1.11	838.15M	581.12M	-212.92M	-174.22M	-0.2738
TMO Thermo Fisher Scientific Inc	451.65	165.75B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	165.75	117.48B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	538.30	41.70B	4.45B	1.10B	1.06B	13.59
WAT Waters Corp	335.29	32.89B	3.77B	449.25M	240.68M	7.8556
A Agilent Technologies Inc	114.00	31.86B	7.07B	1.29B	993.00M	4.5355

Opko Health Inc Stock (OPK) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-11-20	Eingeleitet	JP Morgan	Neutral
2025-10-31	Herabstufung	Jefferies	Buy → Hold
2025-04-25	Eingeleitet	JP Morgan	Neutral
2023-06-29	Hochstufung	Barrington Research	Mkt Perform → Outperform
2022-12-15	Eingeleitet	H.C. Wainwright	Buy
2022-01-24	Herabstufung	Barrington Research	Outperform → Mkt Perform
2021-06-21	Eingeleitet	Ladenburg Thalmann	Buy
2019-11-25	Eingeleitet	Piper Jaffray	Overweight
2018-03-02	Herabstufung	JP Morgan	Neutral → Underweight
2017-09-14	Herabstufung	JP Morgan	Overweight → Neutral
2016-06-21	Bestätigt	Standpoint Research	Buy
2016-06-03	Eingeleitet	Standpoint Research	Buy
2016-03-31	Bestätigt	Barrington Research	Outperform
2015-10-16	Eingeleitet	JP Morgan	Overweight
2015-09-11	Herabstufung	Jefferies	Buy → Hold
2015-03-03	Herabstufung	Oppenheimer	Outperform → Perform
2014-05-12	Bestätigt	Oppenheimer	Outperform
2014-03-14	Eingeleitet	Oppenheimer	Outperform
2013-11-13	Bestätigt	Ladenburg Thalmann	Buy
2013-05-30	Bestätigt	Ladenburg Thalmann	Buy
2012-10-22	Eingeleitet	Barrington Research	Outperform
2011-12-01	Bestätigt	Ladenburg Thalmann	Buy
2011-07-14	Eingeleitet	Ladenburg Thalmann	Buy

Alle ansehen

Opko Health Inc Aktie (OPK) Neueste Nachrichten

12:51 PM

OPKO Health stock (US68375N1037): Genomics leader with recent subsidiary activity - AD HOC NEWS

12:51 PM

08:19 AM

OPKO Health (OPK) price target increased by 11.18% to 3.86 - MSN

08:19 AM

May 12, 2026

ModeX to present preclinical CAR-T data at gene therapy meeting - Investing.com UK

May 12, 2026

OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies - Yahoo Finance

May 12, 2026

May 11, 2026

OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

May 06, 2026

May 05, 2026

MSN Money - MSN

May 05, 2026

OPK Stock Price, Quote & Chart | OPKO HEALTH INC (NASDAQ:OPK) - ChartMill

May 05, 2026

May 03, 2026

OPKO Health, Inc. (NASDAQ:OPK) Just Reported And Analysts Have Been Lifting Their Price Targets - 富途牛牛

May 03, 2026

May 01, 2026

HC Wainwright Boosts Earnings Estimates for OPKO Health - MarketBeat

May 01, 2026

OPKO Health : Notice Annual Meeting of stockholders be held on Thursday, June 18, 2026. - marketscreener.com

May 01, 2026

Apr 30, 2026

OPKO gains 15% stake in Nicoya for China RAYALDEE rights - Investing.com UK

Apr 30, 2026

[ARS] OPKO HEALTH, INC. SEC Filing - Stock Titan

Apr 30, 2026

Board structure and pay detailed in OPKO Health (NASDAQ: OPK) 2026 proxy - Stock Titan

Apr 30, 2026

OPKO gains 15% stake in Nicoya for China RAYALDEE rights By Investing.com - Investing.com South Africa

Apr 30, 2026

OPKO Health receives 15% stake in Nicoya for China drug rights - StreetInsider

Apr 30, 2026

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China - marketscreener.com

Apr 30, 2026

Q1 Earnings Estimate for OPKO Health Issued By HC Wainwright - MarketBeat

Apr 30, 2026

Order lab tests online or at home: BioReference opens new platform - Stock Titan

Apr 30, 2026

BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform - ChartMill

Apr 30, 2026

Apr 29, 2026

OPKO Health (OPK) reports Q1 loss, misses revenue estimates - MSN

Apr 29, 2026

OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y - sharewise.com

Apr 29, 2026

OPKO Health Down Over 13%, On Pace for Largest Percent Decrease Since January 2024 -- Data Talk - Moomoo

Apr 29, 2026

OPKO Health (NASDAQ:OPK) Hits New 1-Year LowShould You Sell? - MarketBeat

Apr 29, 2026

This Purple Innovation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga

Apr 29, 2026

H.C. Wainwright reiterates Opko Health stock rating on Q1 results By Investing.com - Investing.com Australia

Apr 29, 2026

OPKO Health (NASDAQ:OPK) Downgraded to "Market Perform" Rating by Barrington Research - MarketBeat

Apr 29, 2026

H.C. Wainwright reiterates Opko Health stock rating on Q1 results - Investing.com

Apr 29, 2026

OPKO Health Q1 2026 Earnings Call: Complete Transcript - Benzinga

Apr 29, 2026